Alternative mechanisms for tiotropium

Pulmonary Pharmacology and Therapeutics

Volumn 22, Issue 6, 2009, Pages 533-542

  Bateman, E D ^a   Rennard, S ^b   Barnes, P J ^c   Dicpinigaitis, P V ^d   Gosens, R ^e   Gross, N J ^f   Nadel, J A ^g   Pfeifer, M ^h   Racke K ⁱ   Rabe, K F ^j   Rubin, B K ^k   Welte, T ^l   Wessler, I ^m  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^d MONTEFIORE MEDICAL CENTER   (United States)

^e UNIVERSITY OF GRONINGEN   (Netherlands)

^f LOYOLA UNIVERSITY CHICAGO   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF REGENSBURG   (Germany)

ⁱ UNIVERSITY OF BONN   (Germany)

^j LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^k WAKE FOREST SCHOOL OF MEDICINE   (United States)

^l HANNOVER MEDICAL SCHOOL   (Germany)

^m JOHANNES GUTENBERG UNIVERSITY   (Germany)

more..

Author keywords

COPD; Cough; Inflammation; Mechanisms; Mucus; Remodelling; Tiotropium

Indexed keywords

ACETYLCHOLINE; ANTITUSSIVE AGENT; ATROPINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; INTERLEUKIN 8; IPRATROPIUM BROMIDE; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NICOTINIC RECEPTOR; OXITROPIUM BROMIDE; PLACEBO; TERFENADINE; TIOTROPIUM BROMIDE; TRANSFORMING GROWTH FACTOR BETA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BRONCHUS MUCUS; BRONCHUS TONE; CELL PROLIFERATION; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COUGHING; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MECHANISM; EPITHELIUM CELL; FIBROBLAST; GENETIC POLYMORPHISM; HUMAN; INFLAMMATORY CELL; LUNG FUNCTION; MUCUS SECRETION; MUSCLE RELAXATION; NONHUMAN; PARASYMPATHETIC INNERVATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; RISK FACTOR; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTILITY; SPIROMETRY; SPUTUM ANALYSIS; UPPER RESPIRATORY TRACT INFECTION;

ACETYLCHOLINE; ANIMALS; BRONCHODILATOR AGENTS; CHOLINERGIC ANTAGONISTS; COUGH; HUMANS; INFLAMMATION; LUNG; MUCUS; PARASYMPATHETIC NERVOUS SYSTEM; RESPIRATORY SYSTEM; SCOPOLAMINE DERIVATIVES;

EID: 71249094666     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2009.06.002     Document Type: Article

References (97)

1. Casaburi R., Mahler D.A., Jones P.W., Wanner A., San Pedro G., ZuWallack R.L., et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 19 (2002) 217-224
2. Vincken W., van Noord J.A., Greefhorst A.P.M., Bantje Th.A., Kesten S., Korducki L., et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 19 (2002) 209-216
3. Brusasco V., Hodder R., Miravitlles M., Korducki L., Towse L., and Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 58 5 (2003) 399-404
4. Anzueto A., Tashkin D., Menjoge S., and Kesten S. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm Pharmacol Ther 18 2 (2005) 75-81
5. Decramer M., Celli B., Tashkin D.P., Pauwels R.A., Burkhart D., Cassino C., et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. COPD 1 2 (2004) 303-312
6. Tashkin D.P., Celli B., Senn S., Burkhart D., Kesten S., Menjoge S., et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359 15 (2008) 1543-1554
7. Nadel J., Barnes P.J., and Holtzman M.J. Autonomic factors in hyperreactivity of airway smooth muscle. Handbook of physiology: the respiratory system (1986), American Physiological Society 693-702
8. Racke K., and Matthiesen S. The airway cholinergic system: physiology and pharmacology. Pulm Pharmacol Ther 17 4 (2004) 181-198
9. Belmonte K.E. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc Am Thorac Soc 2 4 (2005) 297-304
10. Proskocil B.J., and Fryer A.D. Beta2-agonist and anticholinergic drugs in the treatment of lung disease. Proc Am Thorac Soc 2 4 (2005) 305-310
11. Zhou H., Meyer A., Starke K., Gomeza J., Wess J., and Trendelenburg A.U. Heterogeneity of release-inhibiting muscarinic autoreceptors in heart atria and urinary bladder: a study with M(2)- and M(4)-receptor-deficient mice. Naunyn Schmiedebergs Arch Pharmacol 365 2 (2002) 112-122
12. Gross N.J., Co E., and Skorodin M.S. Cholinergic bronchomotor tone in COPD. Estimates of its amount in comparison with that in normal subjects. Chest 96 5 (1989) 984-987
13. Hansel T.T., and Barnes P.J. Tiotropium bromide: a novel once-daily anticholinergic bronchodilator for the treatment of COPD. Drugs Today (Barc) 38 9 (2002) 585-600
14. Wessler I., Kirkpatrick C.J., and Racke K. The cholinergic 'pitfall': acetylcholine, a universal cell molecule in biological systems, including humans. Clin Exp Pharmacol Physiol 26 3 (1999) 198-205
15. Horiuchi Y., Kimura R., Kato N., Fujii T., Seki M., Endo T., et al. Evolutional study on acetylcholine expression. Life Sci 72 15 (2003) 1745-1756
16. Wessler I., Roth E., Deutsch C., Brockerhoff P., Bittinger F., Kirkpatrick C.J., et al. Release of non-neuronal acetylcholine from the isolated human placenta is mediated by organic cation transporters. Br J Pharmacol 134 5 (2001) 951-956
17. Kummer W., Wiegand S., Akinci S., Wessler I., Schinkel A.H., Wess J., et al. Role of acetylcholine and polyspecific cation transporters in serotonin-induced bronchoconstriction in the mouse. Respir Res 7 (2006) 65
18. Lips K.S., Volk C., Schmitt B.M., Pfeil U., Arndt P., Miska D., et al. Polyspecific cation transporters mediate luminal release of acetylcholine from bronchial epithelium. Am J Respir Cell Mol Biol 33 1 (2005) 79-88
19. Grando S.A., Pittelkow M.R., and Schallreuter K.U. Adrenergic and cholinergic control in the biology of epidermis: physiological and clinical significance. J Invest Dermatol 126 9 (2006) 1948-1965
20. Grando S.A., Kawashima K., Kirkpatrick C.J., and Wessler I. Recent progress in understanding the non-neuronal cholinergic system in humans. Life Sci 80 24-25 (2007) 2181-2185
21. Kunz L., Roggors C., and Mayerhofer A. Ovarian acetylcholine and ovarian KCNQ channels: insights into cellular regulatory systems of steroidogenic granulosa cells. Life Sci 80 24-25 (2007) 2195-2198
22. Wessler I., Reinheimer T., Kilbinger H., Bittinger F., Kirkpatrick C.J., Saloga J., et al. Increased acetylcholine levels in skin biopsies of patients with atopic dermatitis. Life Sci 72 18-19 (2003) 2169-2172
23. Folkerts G., and Nijkamp F.P. Airway epithelium: more than just a barrier!. Trends Pharmacol Sci 19 8 (1998) 334-341
24. Schulz C., Kratzel K., Wolf K., Schroll S., Kohler M., and Pfeifer M. Activation of bronchial epithelial cells in smokers without airway obstruction and patients with COPD. Chest 125 5 (2004) 1706-1713
25. Klapproth H., Reinheimer T., Metzen J., Munch M., Bittinger F., Kirkpatrick C.J., et al. Non-neuronal acetylcholine, a signalling molecule synthezised by surface cells of rat and man. Naunyn Schmiedebergs Arch Pharmacol 355 4 (1997) 515-523
26. Mak J.C., and Barnes P.J. Muscarinic receptor subtypes in human and guinea pig lung. Eur J Pharmacol 164 2 (1989) 223-230
27. Wessler I.K., and Kirkpatrick C.J. The non-neuronal cholinergic system: an emerging drug target in the airways. Pulm Pharmacol Ther 14 6 (2001) 423-434
28. Acevedo M. Effect of acetyl choline on ion transport in sheep tracheal epithelium. Pflugers Arch 427 5-6 (1994) 543-546
29. Disse B., Speck G.A., Rominger K.L., Witek Jr. T.J., and Hammer R. Tiotropium (Spiriva™): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 64 6/7 (1999) 457-464
30. Wessler I., Kilbinger H., Bittinger F., and Kirkpatrick C.J. The biological role of non-neuronal acetylcholine in plants and humans. Jpn J Pharmacol 85 1 (2001) 2-10
31. Koyama S., Rennard S.I., and Robbins R.A. Acetylcholine stimulates bronchial epithelial cells to release neutrophil and monocyte chemotactic activity. Am J Physiol 262 4 Pt 1 (1992) L466-L471
32. Koyama S., Sato E., Nomura H., Kubo K., Nagai S., and Izumi T. Acetylcholine and substance P stimulate bronchial epithelial cells to release eosinophil chemotactic activity. J Appl Physiol 84 5 (1998) 1528-1534
33. Nadel J.A. Innate immune mucin production via epithelial cell surface signaling: relationship to allergic disease. Curr Opin Allergy Clin Immunol 7 1 (2007) 57-62
34. Daub H., Wallasch C., Lankenau A., Herrlich A., and Ullrich A. Signal characteristics of G protein-transactivated EGF receptor. EMBO J 16 23 (1997) 7032-7044
35. Dong J., Opresko L.K., Dempsey P.J., Lauffenburger D.A., Coffey R.J., and Wiley H.S. Metalloprotease-mediated ligand release regulates autocrine signaling through the epidermal growth factor receptor. Proc Natl Acad Sci U S A 96 11 (1999) 6235-6240
36. Kanno H., Horikawa Y., Hodges R.R., Zoukhri D., Shatos M.A., Rios J.D., et al. Cholinergic agonists transactivate EGFR and stimulate MAPK to induce goblet cell secretion. Am J Physiol Cell Physiol 284 4 (2003) C988-C998
37. Shao M.X., and Nadel J.A. Dual oxidase 1-dependent MUC5AC mucin expression in cultured human airway epithelial cells. Proc Natl Acad Sci U S A 102 3 (2005) 767-772
38. Barnes P.J., Shapiro S.D., and Pauwels R.A. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 22 4 (2003) 672-688
39. Kawashima K., and Fujii T. Expression of non-neuronal acetylcholine in lymphocytes and its contribution to the regulation of immune function. Front Biosci 9 (2004) 2063-2085
40. Carlisle D.L., Hopkins T.M., Gaither-Davis A., Silhanek M.J., Luketich J.D., Christie N.A., et al. Nicotine signals through muscle-type and neuronal nicotinic acetylcholine receptors in both human bronchial epithelial cells and airway fibroblasts. Respir Res 5 (2004) 27
41. Buhling F., Lieder N., Kuhlmann U.C., Waldburg N., and Welte T. Tiotropium suppresses acetylcholine-induced release of chemotactic mediators in vitro. Respir Med 101 11 (2007) 2386-2394
42. Triggiani M., Gentile M., Secondo A., Granata F., Oriente A., Taglialatela M., et al. Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors. J Immunol 166 6 (2001) 4083-4091
43. Kalenderian R., Raju L., Roth W., Schwartz L.B., Gruber B., and Janoff A. Elevated histamine and tryptase levels in smokers' bronchoalveolar lavage fluid. Do lung mast cells contribute to smokers' emphysema?. Chest 94 1 (1988) 119-123
44. Rutgers S.R., Koeter G.H., Van Der Mark T.W., and Postma D.S. Protective effect of oral terfenadine and not inhaled ipratropium on adenosine 5′-monophosphate-induced bronchoconstriction in patients with COPD. Clin Exp Allergy 29 9 (1999) 1287-1292
45. Reinheimer T., Mohlig T., Zimmermann S., Hohle K.D., and Wessler I. Muscarinic control of histamine release from airways. Inhibitory M1-receptors in human bronchi but absence in rat trachea. Am J Respir Crit Care Med 162 2 Pt 1 (2000) 534-538
46. Bos I.S., Gosens R., Zuidhof A.B., Schaafsma D., Halayko A.J., Meurs H., et al. Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison. Eur Respir J 30 4 (2007) 653-661
47. An S.S., Bai T.R., Bates J.H., Black J.L., Brown R.H., Brusasco V., et al. Airway smooth muscle dynamics: a common pathway of airway obstruction in asthma. Eur Respir J 29 5 (2007) 834-860
48. Chung K.F. The role of airway smooth muscle in the pathogenesis of airway wall remodeling in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2 4 (2005) 347-354
49. Hogg J.C., Chu F., Utokaparch S., Woods R., Elliott W.M., Buzatu L., et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350 26 (2004) 2645-2653
50. Opazo Saez A.M., Seow C.Y., and Pare P.D. Peripheral airway smooth muscle mechanics in obstructive airways disease. Am J Respir Crit Care Med 161 3 Pt 1 (2000) 910-917
51. Gosens R., Zaagsma J., Grootte B.M., Nelemans A., and Meurs H. Acetylcholine: a novel regulator of airway smooth muscle remodelling?. Eur J Pharmacol 500 1-3 (2004) 193-201
52. Gosens R., Nelemans S.A., Grootte Bromhaar M.M., McKay S., Zaagsma J., and Meurs H. Muscarinic M3-receptors mediate cholinergic synergism of mitogenesis in airway smooth muscle. Am J Respir Cell Mol Biol 28 2 (2003) 257-262
53. Gosens R., Dueck G., Rector E., Nunes R.O., Gerthoffer W.T., Unruh H., et al. Cooperative regulation of GSK-3 by muscarinic and PDGF receptors is associated with airway myocyte proliferation. Am J Physiol Lung Cell Mol Physiol 293 5 (2007) L1348-L1358
54. Billington C.K., Kong K.C., Bhattacharyya R., Wedegaertner P.B., Panettieri Jr. R.A., Chan T.O., et al. Cooperative regulation of p70S6 kinase by receptor tyrosine kinases and G protein-coupled receptors augments airway smooth muscle growth. Biochemistry 44 44 (2005) 14595-14605
55. Krymskaya V.P., Orsini M.J., Eszterhas A.J., Brodbeck K.C., Benovic J.L., Panettieri Jr. R.A., et al. Mechanisms of proliferation synergy by receptor tyrosine kinase and G protein-coupled receptor activation in human airway smooth muscle. Am J Respir Cell Mol Biol 23 4 (2000) 546-554
56. Gosens R., Bos I.S., Zaagsma J., and Meurs H. Protective effects of tiotropium bromide in the progression of airway smooth muscle remodeling. Am J Respir Crit Care Med 171 10 (2005) 1096-1102
57. Liu H.W., Halayko A.J., Fernandes D.J., Harmon G.S., McCauley J.A., Kocieniewski P., et al. The rhoA/rho kinase pathway regulates nuclear localization of serum response factor. Am J Respir Cell Mol Biol 29 1 (2003) 39-47
58. Liu H.W., Kassiri K., Voros A., Hillier C.T., Wang L., Solway J., et al. Gaq-receptor coupled signaling induces RHO-dependent transcription of smooth muscle specific genes in cultured canine airway myocytes. Am J Respir Crit Care Med 165 (2002) A670
59. Kanefsky J., Lenburg M., and Hai C.M. Cholinergic receptor and cyclic stretch-mediated inflammatory gene expression in intact ASM. Am J Respir Cell Mol Biol 34 4 (2006) 417-425
60. Matthiesen S., Bahulayan A., Kempkens S., Haag S., Fuhrmann M., Stichnote C., et al. Muscarinic receptors mediate stimulation of human lung fibroblast proliferation. Am J Respir Cell Mol Biol 35 6 (2006) 621-627
61. Matthiesen S., Bahulayan A., Holz O., and Racke K. MAPK pathway mediates muscarinic receptor-induced human lung fibroblast proliferation. Life Sci 80 24-25 (2007) 2259-2262
62. Haag S., Matthiesen S., Juergens U.R., and Racke K. Muscarinic receptors mediate stimulation of collagen synthesis in human lung fibroblasts. Eur Respir J 32 3 (2008) 555-562
63. Racke K., Haag S., Bahulayan A., and Warnken M. Pulmonary fibroblasts, an emerging target for anti-obstructive drugs. Naunyn Schmiedebergs Arch Pharmacol 378 2 (2008) 193-201
64. Pieper M.P., Chaudhary N.I., and Park J.E. Acetylcholine-induced proliferation of fibroblasts and myofibroblasts in vitro is inhibited by tiotropium bromide. Life Sci 80 24-25 (2007) 2270-2273
65. Barnes P.J. Tiotropium bromide. Expert Opin Investig Drugs 10 4 (2001) 733-740
66. Annis P., Landa J., and Lichtiger M. Effects of atropine on velocity of tracheal mucus in anesthetized patients. Anesthesiology 44 1 (1976) 74-77
67. Groth M.L., Langenback E.G., and Foster W.M. Influence of inhaled atropine on lung mucociliary function in humans. Am Rev Respir Dis 144 5 (1991) 1042-1047
68. Kishioka C., Okamoto K., Kim J., and Rubin B.K. Regulation of secretion from mucous and serous cells in the excised ferret trachea. Respir Physiol 126 2 (2001) 163-171
69. Francis R.A., Thompson M.L., Pavia D., and Douglas R.B. Ipratropium bromide: mucociliary clearance rate and airway resistance in normal subjects. Br J Dis Chest 71 3 (1977) 173-178
70. Ruffin R.E., Wolff R.K., Dolovich M.B., Rossman C.M., Fitzgerald J.D., and Newhouse M.T. Aerosol therapy with Sch 1000. Short-term mucociliary clearance in normal and bronchitic subjects and toxicology in normal subjects. Chest 73 4 (1978) 501-506
71. Pavia D., Bateman J.R., Sheahan N.F., and Clarke S.W. Effect of ipratropium bromide on mucociliary clearance and pulmonary function in reversible airways obstruction. Thorax 34 4 (1979) 501-507
72. Matthys H., Hundenborn J., Daikeler G., and Kohler D. Influence of 0.2 mg ipratropium bromide on mucociliary clearance in patients with chronic bronchitis. Respiration 48 4 (1985) 329-339
73. Taylor R.G., Pavia D., Agnew J.E., Lopez-Vidriero M.T., Newman S.P., Lennard-Jones T., et al. Effect of four weeks' high dose ipratropium bromide treatment on lung mucociliary clearance. Thorax 41 4 (1986) 295-300
74. Bennett W.D., Chapman W.F., and Mascarella J.M. The acute effect of ipratropium bromide bronchodilator therapy on cough clearance in COPD. Chest 103 2 (1993) 488-495
75. Guleria R., Singh T.R., Sinha S., Padhy K., Gupta K., and Pande J.N. Effect of single inhalation of a salbutamol, ipratropium bromide and beclomethasone on mucociliary clearance in patients with chronic obstructive airway disease. Indian J Chest Dis Allied Sci 45 4 (2003) 241-246
76. Tamaoki J., Chiyotani A., Tagaya E., Sakai N., and Konno K. Effect of long term treatment with oxitropium bromide on airway secretion in chronic bronchitis and diffuse panbronchiolitis. Thorax 49 6 (1994) 545-548
77. Hasani A., Toms N., Agnew J.E., Sarno M., Harrison A.J., and Dilworth P. The effect of inhaled tiotropium bromide on lung mucociliary clearance in patients with COPD. Chest 125 5 (2004) 1726-1734
78. Vestbo J. Epidemiological studies in mucus hypersecretion. In: Chadwick D.J., and Goode J.A. (Eds). Symposium on mucus hypersecretion in respiratory disease (2002), Novartis Foundation, London 3-12
79. Prescott E., Lange P., and Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur Respir J 8 8 (1995) 1333-1338
80. Bolser D.C. Current and future centrally acting antitussives. Respir Physiol Neurobiol 152 3 (2006) 349-355
81. Irwin R.S., Baumann M.H., Bolser D.C., Boulet L.P., Braman S.S., Brightling C.E., et al. Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. Chest 129 1 Suppl (2006) 1S-23S
82. Widdicombe J.G. Neurophysiology of the cough reflex. Eur Respir J 8 7 (1995) 1193-1202
83. Holmes P.W., Barter C.E., and Pierce R.J. Chronic persistent cough: use of ipratropium bromide in undiagnosed cases following upper respiratory tract infection. Respir Med 86 5 (1992) 425-429
84. Pounsford J.C., Birch M.J., and Saunders K.B. Effect of bronchodilators on the cough response to inhaled citric acid in normal and asthmatic subjects. Thorax 40 9 (1985) 662-667
85. Lowry R., Wood A., Johnson T., and Higenbottam T. Antitussive properties of inhaled bronchodilators on induced cough. Chest 93 6 (1988) 1186-1189
86. Lowry R., Wood A., and Higenbottam T. The effect of anticholinergic bronchodilator therapy on cough during upper respiratory tract infections. Br J Clin Pharmacol 37 2 (1994) 187-191
87. Dicpinigaitis P.V., Spinner L.M., Santhyadka G.S., and Negassa A. Effect of tiotropium on cough reflex sensitivity in acute viral cough. Lung 186 (2008) 369-374
88. Nichol G., Nix A., Barnes P.J., and Chung K.F. Prostaglandin F2 alpha enhancement of capsaicin induced cough in man: modulation by beta 2 adrenergic and anticholinergic drugs. Thorax 45 9 (1990) 694-698
89. Smith C.A., Adamson D.L., Choudry N.B., and Fuller R.W. The effect of altering airway tone on the sensitivity of the cough reflex in normal volunteers. Eur Respir J 4 9 (1991) 1078-1079
90. Fujimura M., Sakamoto S., Kamio Y., and Matsuda T. Effects of methacholine induced bronchoconstriction and procaterol induced bronchodilation on cough receptor sensitivity to inhaled capsaicin and tartaric acid. Thorax 47 6 (1992) 441-445
91. Powrie D.J., Wilkinson T.M., Donaldson G.C., Jones P., Scrine K., Viel K., et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in chronic obstructive pulmonary disease. Eur Respir J 30 3 (2007) 472-478
92. Tschumperlin D.J., and Drazen J.M. Chronic effects of mechanical force on airways. Annu Rev Physiol 68 (2006) 563-583
93. Hogg J.C. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 364 9435 (2004) 709-721
94. Jeffery P.K. Comparison of the structural and inflammatory features of COPD and asthma. Giles F Filley lecture. Chest 117 5 (2000) 251S-260S
95. O'Donnell D.E., Flüge T., Gerken F., Hamilton A., Webb K., Aguilaniu B., et al. Effects of tiotropium on lung hyperinflation, dyspnea and exercise tolerance in patients with COPD. Eur Respir J 23 6 (2004) 832-840
96. Anthonisen N.R., Connett J.E., Kiley J.P., Altose M.D., Bailey W.C., Buist A.S., et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The lung health study. J Am Med Assoc 272 19 (1994) 1497-1505
97. Troosters T., Kesten S., Burkhart D., Celli B., Liu D., Mehra S., et al. Effectiveness of tiotropium as first maintenance drug in patients with COPD. Secondary analysis of the UPLIFT trial. Am J Respir Crit Care Med 179 (2009) A2467 [abstract]